Lindsey Rolfe - 01 Feb 2022 Form 4 Insider Report for Clovis Oncology, Inc.

Role
Officer
Signature
/s/ Lindsey Rolfe
Issuer symbol
N/A
Transactions as of
01 Feb 2022
Net transactions value
-$8,756
Form type
4
Filing time
03 Feb 2022, 15:17:12 UTC
Previous filing
03 Dec 2021
Next filing
03 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +3,750 +4.5% 86,378 01 Feb 2022 Direct F1
transaction CLVS Common Stock Sale $3,920 -2,021 -2.3% $1.94* 84,357 02 Feb 2022 Direct F2, F3
transaction CLVS Common Stock Options Exercise +4,625 +5.5% 88,982 01 Feb 2022 Direct F1
transaction CLVS Common Stock Sale $4,836 -2,493 -2.8% $1.94* 86,489 02 Feb 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 -3,750 -20% $0.000000 14,997 01 Feb 2022 Common Stock 3,750 Direct F1, F4
transaction CLVS Restricted Stock Units Options Exercise $0 -4,625 -11% $0.000000 37,000 01 Feb 2022 Common Stock 4,625 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F5 On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance